Analysts predict that MEDNAX Inc (NYSE:MD) will announce sales of $875.46 million for the current fiscal quarter, according to Zacks. Eight analysts have provided estimates for MEDNAX’s earnings. The lowest sales estimate is $860.00 million and the highest is $881.50 million. MEDNAX posted sales of $896.65 million in the same quarter last year, which suggests a negative year over year growth rate of 2.4%. The company is scheduled to report its next earnings report on Thursday, November 7th.

On average, analysts expect that MEDNAX will report full year sales of $3.49 billion for the current financial year, with estimates ranging from $3.47 billion to $3.51 billion. For the next fiscal year, analysts forecast that the business will post sales of $3.58 billion, with estimates ranging from $3.52 billion to $3.64 billion. Zacks Investment Research’s sales calculations are an average based on a survey of research analysts that that provide coverage for MEDNAX.

MEDNAX (NYSE:MD) last posted its earnings results on Thursday, August 1st. The company reported $0.89 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.78 by $0.11. MEDNAX had a negative net margin of 3.53% and a positive return on equity of 9.34%. The firm had revenue of $868.31 million during the quarter, compared to analysts’ expectations of $868.71 million. During the same period in the previous year, the business posted $1.07 EPS. The business’s revenue was up .4% compared to the same quarter last year.

MD has been the subject of several analyst reports. UBS Group decreased their target price on shares of MEDNAX to $20.00 and set a “sell” rating for the company in a research note on Wednesday, July 24th. Zacks Investment Research cut shares of MEDNAX from a “hold” rating to a “sell” rating and set a $26.00 target price for the company. in a research note on Wednesday, July 3rd. Credit Suisse Group decreased their target price on shares of MEDNAX from $30.00 to $28.00 and set an “outperform” rating for the company in a research note on Tuesday, August 27th. BMO Capital Markets decreased their target price on shares of MEDNAX from $32.00 to $25.00 and set a “market perform” rating for the company in a research note on Monday, August 5th. Finally, Mizuho decreased their target price on shares of MEDNAX from $26.00 to $24.00 and set a “neutral” rating for the company in a research note on Friday, August 2nd. Four research analysts have rated the stock with a sell rating, five have given a hold rating and three have issued a buy rating to the stock. The company has an average rating of “Hold” and an average price target of $28.30.

In related news, Director Michael Fernandez acquired 122,409 shares of MEDNAX stock in a transaction on Monday, August 12th. The stock was bought at an average cost of $21.35 per share, for a total transaction of $2,613,432.15. Following the completion of the transaction, the director now owns 350,288 shares of the company’s stock, valued at approximately $7,478,648.80. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Md Pascal J. Goldschmidt sold 5,000 shares of the stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $20.81, for a total transaction of $104,050.00. Following the completion of the sale, the director now owns 15,821 shares of the company’s stock, valued at $329,235.01. The disclosure for this sale can be found here. Corporate insiders own 3.40% of the company’s stock.

Several hedge funds and other institutional investors have recently modified their holdings of MD. Quadrant Capital Group LLC grew its holdings in shares of MEDNAX by 538.6% in the first quarter. Quadrant Capital Group LLC now owns 1,009 shares of the company’s stock valued at $26,000 after purchasing an additional 851 shares during the period. Bremer Bank National Association purchased a new stake in shares of MEDNAX in the first quarter valued at about $30,000. Meeder Asset Management Inc. purchased a new stake in shares of MEDNAX in the second quarter valued at about $36,000. Twin Tree Management LP grew its holdings in shares of MEDNAX by 637.7% in the first quarter. Twin Tree Management LP now owns 4,242 shares of the company’s stock valued at $115,000 after purchasing an additional 3,667 shares during the period. Finally, US Bancorp DE grew its holdings in shares of MEDNAX by 38.5% in the second quarter. US Bancorp DE now owns 5,657 shares of the company’s stock valued at $142,000 after purchasing an additional 1,572 shares during the period. Institutional investors and hedge funds own 92.26% of the company’s stock.

Shares of MD traded down $0.79 during trading hours on Tuesday, hitting $23.18. The stock had a trading volume of 1,253,070 shares, compared to its average volume of 732,534. The company has a debt-to-equity ratio of 0.79, a quick ratio of 2.23 and a current ratio of 2.23. The firm has a 50-day moving average price of $21.96 and a 200 day moving average price of $25.79. MEDNAX has a fifty-two week low of $19.93 and a fifty-two week high of $48.50. The firm has a market capitalization of $1.98 billion, a price-to-earnings ratio of 6.60, a PEG ratio of 0.91 and a beta of 0.73.

About MEDNAX

MEDNAX, Inc, together with its subsidiaries, provides newborn, anesthesia, maternal-fetal, radiology and teleradiology, pediatric cardiology, and other pediatric subspecialty physician services in the United States and Puerto Rico. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians; anesthesia and anesthesia subspecialty care services; and acute and chronic pain management services.

Further Reading: What is dividend yield?

Get a free copy of the Zacks research report on MEDNAX (MD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for MEDNAX (NYSE:MD)

Receive News & Ratings for MEDNAX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEDNAX and related companies with MarketBeat.com's FREE daily email newsletter.